Attenuated virus vector system, application of attenuated virus vector system in preparation of anti-malignant tumor drugs and drug use method

Abstract

The invention discloses an attenuated virus vector system, an application of the attenuated virus vector system in preparation of anti-malignant tumor drugs and a drug use method. The virus is RNA virus, its genetic material does not have integration capability in the mammalian cells, and the virus belongs to the field of rhabdoviridae and vesicular stomatitis viruses. The virus vector system structure gene chimeric coding molecule at least comprises an inhibitor specific to an immune checkpoint molecule, the attenuated virus vector system is a novel recombinant expression vector system for chimeric expression of a single-chain antibody aiming at an immune checkpoint, the replication can be specifically completed in tumor cells, and meanwhile, specific antibodies secreting molecules binding to the surfaces of the tumor cells can be expressed, the tumor antigen is released, the anti-tumor specific immune response of immune cells is activated at the same time, meanwhile, the secreted single-chain antibody breaks the immunosuppressive effect of the tumor microenvironment, the removal of CTL cells to tumor cells is promoted, a systematic specific anti-tumor immune memory reaction of anorganism is promoted, and the recurrence of tumors is controlled.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to an attenuated virus vector system and its application in the preparation of anti-malignant medicaments and a method for using the medicaments. Background technique [0002] The range of treatment options available to cancer patients has changed dramatically over the past decade. With the understanding of driver mutations related to tumor growth and development, coupled with the development of these specific mutation-targeted molecular inhibitors, a new field of tumor treatment, namely precision oncology, has emerged. Tumor immunotherapy The theoretical basis is that the immune system has the ability to recognize tumor-associated antigens and regulate the body's ability to attack tumor cells (highly specific cytolysis). This biological process is very complex and is still under a lot of basic research. [0003] In the 1990s, several scientific research groups have discovered tumor ant...

AI Technical Summary

Problems solved by technology

[0005] While cure rates for several malignancies have now been dramatically improved through decades of research into the development of new technologies and therapies in cancer treatment, outcomes for patients with advanced solid tumors have remained brutally unchanged over the past few decades , which emphasizes the need for new therapies. Antibodies against tumor immune checkpoints, such as PD-1 / PD-L1 and CTLA4, have been put into clinical use in solid tumors. These monoclonal antibodies that effectively antagonize immune checkpoint molecules The key point is the effective production capacity per unit volume. In addition, the problem of drug resistance of immune checkpoint antibodies needs to be solved urgently. The current research progress of tumor immunotherapy has attracted the attention of various countries

Images